The Parker Institute for Cancer Immunotherapy and start-up Xyphos Biosciences are teaming up to develop universal and controllable CAR T-cell therapies that can treat many kinds of cancers. Whereas the two CAR T-cell therapies on the market are engineered to attack one particular protein, Xyphos is designing what it calls convertible CAR T cells, which can be redirected to many targets. The cells are activated by bispecific antibodies that bind a CAR T cell at one end and the cancer cell at the other end. Xyphos expects to test its first therapy in humans in early 2020.
You Might Also Like...
Parker-backed cancer scientists shine a light on an emerging pathway in pancreatic cancer
Endpoints News | January 14, 2019
Immunotherapy 2.0: Improving the Response to Checkpoint Inhibitors
JAMA | December 19, 2018